Report overview
Biogenerics drugs are the biological products manufactured after end of patent of innovator biopharmaceuticals. Biogenerics also known as biosimilars in Europe, follows-on-biologics in US and subsequent entry biological in japan. Due to their high degree of similarity with the biological reference product, they have no clinically evidenced and meaningful differences from the reference product in terms of quality, safety or efficacy. Biogenerics drugs provide effective treatment for number of serious and life-threatening illness because of their high specificity and activity. Biogeneric are more complex compared to small molecule drugs. Their quality and safety are highly dependent on the process of production (choice of cell type, development of the genetically modified cell for production, etc.), purification and formulation. The constitution of the biogeneric drugs can be either small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies. Biogeneric drugs are increasing gaining prominence given the loss of exclusivity of big branded drugs. In Europe, biogenerics can be marketed through independent applicant following expiry of patent and market exclusivity periods of the reference product. Regulatory harmonization, naming and labelling, innovative licensure norms and route to market for the biogeneric drugs are issues expected to gain attention and traction from big drug makers in the forthcoming years.
This report aims to provide a comprehensive presentation of the global market for Biogeneric Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biogeneric Drugs. This report contains market size and forecasts of Biogeneric Drugs in global, including the following market information:
Global Biogeneric Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Biogeneric Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Biogeneric Drugs companies in 2022 (%)
The global Biogeneric Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Biogeneric drugs market is expected to increase in forecast period due to increased treatment options, value added services to care patient and healthcare community. Due to drugs introduces competition, increasing affordability of biologics which delivers saving for healthcare systems are the same factors which increase biogeneric drugs market. Introduction of affordable, high-quality biogenerics drugs improves access to life changing medicine for patients worldwide. Opportunities for generic drug products is huge but there are regulations that must be adhered to when strategizing the best ways to maximize a company?s return. Government regulation may be adhere the growth of drug development investment or planning an entry into a market with a new biogeneric products.
We surveyed the Biogeneric Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biogeneric Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biogeneric Drugs Market Segment Percentages, by Type, 2022 (%)
Insulins
Growth Hormones
Monoclonal Antibodies
Others
Global Biogeneric Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biogeneric Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinics
Research Centers
Global Biogeneric Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biogeneric Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biogeneric Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Biogeneric Drugs revenues share in global market, 2022 (%)
Key companies Biogeneric Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Biogeneric Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sandoz International
Teva pharmaceutical industries
Mylan
3SBio
Shanghai Fosun Pharmaceutical
Tonghua Dongbao Pharmaceutical
Biocon
Reliance life sciences
Probiomed
Biosidus
AMEGA Biotech
Celltrion
LG life Science
Dong-A Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biogeneric Drugs, market overview.
Chapter 2: Global Biogeneric Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Biogeneric Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biogeneric Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Biogeneric Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
